BIO-TECHNE Corp
In the published model solve dated 2026-Q2, anchored at $72.36, BIO-TECHNE Corp (TECH) is priced for today's economics sustained for ~11.5 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• Bio-Techne sells the reagents, antibodies, and assays that life-science labs consume, a razor-and-blade catalog where the Protein Sciences segment alone accounted for more than 10 percent of segment net sales across three straight fiscal years, giving the business unusually sticky, recurring demand. • The defining risk is the price: at about 43 times company-wide operating income, no valuation family, asset, earnings, peer, or forward growth, reaches today's level, so the stock is priced for r
Is TECH overvalued? See what's priced in →
566 institutional managers reported holding TECH in 13F filings for the quarter ended 2026-03-31. 59 opened new positions that quarter. Held by Vanguard Group, BlackRock, Morgan Stanley, among others. On the short side, 18.2M shares were sold short as of the 2026-06-15 count, about 12% of shares outstanding (6.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TECH's share count is about flat over the past five years ($536.31M of repurchases, offset by issuance). It pays a dividend, and has paid one every year in our records (17 and counting); the current rate is $0.32 a share annually. Cash returned over the past three years: $138.24M in dividends and $355.80M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at TECH over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TECH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-24 | +2.1% | -21.9% |
| 2023-11-08 | -6.7% | +24.7% |
| 2024-02-08 | -6.2% | +1.2% |
| 2024-05-07 | +19.6% | -8.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TECH's latest 8-K filings: 2026-08-12 (items 2.02, 8.01, 9.01); 2026-06-26 (items 1.01, 5.02, 9.01); 2026-06-25 (items 7.01, 9.01); 2026-05-06 (items 2.02, 8.01, 9.01); 2026-02-11 (items 5.02, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.